Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -29.77%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-10.00%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Polyrizon Ltd.
Market Cap
$10.41M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-10.00%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.46M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-47.37%
3Y Avg
-38.90%
5Y Avg
-35.62%
Market Cap
$10.13M
Return on Invested Capital (ROIC)
-323.71%
TTM Avg
-133.57%
3Y Avg
-246.04%
5Y Avg
-170.10%
Market Cap
$10.13M
Return on Invested Capital (ROIC)
-59.35%
TTM Avg
-68.11%
3Y Avg
-104.39%
5Y Avg
-133.77%
Market Cap
$10.10M
Return on Invested Capital (ROIC)
-95.42%
TTM Avg
-108.10%
3Y Avg
-72.41%
5Y Avg
-59.15%
Market Cap
$10.05M
Return on Invested Capital (ROIC)
-269.16%
TTM Avg
-387.93%
3Y Avg
-400.47%
5Y Avg
-400.47%
Market Cap
$10.01M
Return on Invested Capital (ROIC)
-227.67%
TTM Avg
-121.58%
3Y Avg
-92.03%
5Y Avg
-78.85%
Market Cap
$9.86M
Return on Invested Capital (ROIC)
-55.13%
TTM Avg
-99.85%
3Y Avg
-167.97%
5Y Avg
-308.25%
Market Cap
$9.82M
Return on Invested Capital (ROIC)
-215.61%
TTM Avg
-191.09%
3Y Avg
-141.72%
5Y Avg
-179.96%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polyrizon Ltd. (PLRZ) | $10.41M | N/A | -10.00% | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.46M | N/A | -47.37% | -38.90% | -35.62% |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | -323.71% | -133.57% | -246.04% | -170.10% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.13M | -59.35% | -68.11% | -104.39% | -133.77% |
| Lifeward Ltd. (LFWD)vs › | $10.10M | -95.42% | -108.10% | -72.41% | -59.15% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.05M | -269.16% | -387.93% | -400.47% | -400.47% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.01M | -227.67% | -121.58% | -92.03% | -78.85% |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | -55.13% | -99.85% | -167.97% | -308.25% |
| MetaVia Inc. (MTVA)vs › | $9.82M | -215.61% | -191.09% | -141.72% | -179.96% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.05M | -240.64% | -174.03% | -198.05% | -242.53% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -29.77% |
| 2025-09-30 | -11.83% |
| 2025-06-30 | 0.02% |
| 2025-03-31 | -1.88% |
| 2024-12-31 | -6.54% |
| 2024-09-30 | -12.42% |
